Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. cut its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 7.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,076,431 shares of the biopharmaceutical company's stock after selling 89,560 shares during the quarter. Brown Advisory Inc. owned about 0.91% of Cytokinetics worth $50,635,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Jones Financial Companies Lllp increased its stake in Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 374 shares during the period. Retirement Systems of Alabama boosted its position in shares of Cytokinetics by 0.4% in the fourth quarter. Retirement Systems of Alabama now owns 143,495 shares of the biopharmaceutical company's stock valued at $6,750,000 after acquiring an additional 565 shares during the period. Arizona State Retirement System increased its holdings in shares of Cytokinetics by 1.9% during the 4th quarter. Arizona State Retirement System now owns 32,366 shares of the biopharmaceutical company's stock worth $1,522,000 after purchasing an additional 600 shares during the period. Inspire Investing LLC lifted its position in shares of Cytokinetics by 7.8% in the 4th quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company's stock worth $400,000 after acquiring an additional 616 shares during the period. Finally, Centricity Wealth Management LLC acquired a new stake in Cytokinetics during the fourth quarter worth $29,000.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Barclays started coverage on Cytokinetics in a research report on Thursday, April 24th. They set an "overweight" rating and a $55.00 price target on the stock. Citigroup dropped their price objective on Cytokinetics from $86.00 to $80.00 and set a "buy" rating for the company in a report on Wednesday. Morgan Stanley set a $67.00 price objective on shares of Cytokinetics in a research report on Friday, March 7th. Bank of America reduced their price target on shares of Cytokinetics from $62.00 to $54.00 and set a "neutral" rating for the company in a report on Tuesday, April 15th. Finally, Stifel Nicolaus assumed coverage on shares of Cytokinetics in a research note on Wednesday, January 22nd. They set a "buy" rating and a $80.00 price target for the company. Three research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Cytokinetics presently has a consensus rating of "Moderate Buy" and a consensus target price of $76.41.

Insiders Place Their Bets

In other Cytokinetics news, EVP Andrew Callos sold 2,886 shares of the firm's stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $35.78, for a total transaction of $103,261.08. Following the sale, the executive vice president now directly owns 64,689 shares of the company's stock, valued at $2,314,572.42. This trade represents a 4.27 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total value of $91,960.00. Following the completion of the sale, the executive vice president now directly owns 116,071 shares in the company, valued at $5,336,944.58. This trade represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 95,362 shares of company stock valued at $3,899,118. 2.70% of the stock is owned by insiders.

Cytokinetics Price Performance

Shares of CYTK traded down $0.93 during midday trading on Wednesday, reaching $33.04. The stock had a trading volume of 3,789,651 shares, compared to its average volume of 1,668,693. The company has a market capitalization of $3.94 billion, a price-to-earnings ratio of -6.14 and a beta of 0.81. The company's 50-day moving average is $40.62 and its 200 day moving average is $46.32. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a 12-month low of $32.36 and a 12-month high of $68.44.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, topping the consensus estimate of ($1.41) by $0.05. The company had revenue of $1.60 million during the quarter, compared to analysts' expectations of $2.77 million. The company's revenue for the quarter was up 89.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.33) earnings per share. On average, equities analysts predict that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.